Healthcare
PharmaTher Holdings Ltd.(PHRRF)
Live Price
Offline$0.044
+7.32% today
1Y Change
-83.54%
Window
Jun 23, 2025 → Jun 15, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +51.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PharmaTher Holdings Ltd. (PHRRF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.04 and down 83.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +51.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +51.3%, free cash flow +65.6% with operating margin 0.0% and ROIC -241.0%. Stock Foundry combines PHRRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +51.3%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHRRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHRRF Max Drawdown
-90.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHRRF and SPY.
Company Overview
PharmaTher Holdings Ltd.
Other OTC
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
- Leadership
- Fabio Chianelli
- IPO Date
- Jan 8, 2021
- Street Address
- 82 Richmond Street East
- Mailing
- Toronto, ON, M5C 1P1
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 888 846 3171
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 14.5
Growth
- Revenue
- 0.0%
- EPS
- +51.3%
- Free Cash Flow
- +65.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -155.5%
- ROIC
- -241.0%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 1.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.